This PDF is the current document as it appeared on Public Inspection on 08/18/2016 at 08:45 am.
Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Fax written comments on the collection of information by September 19, 2016.
To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-7285, or emailed to email@example.com. All comments should be identified with the OMB control number 0910-0309. Also include the FDA docket number found in brackets in the heading of this document.Start Further Info
FOR FURTHER INFORMATION CONTACT:
FDA PRA Staff, Office of Operations, Food and Drug Administration, Three White Flint North,10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, PRAStaff@fda.hhs.gov.End Further Info End Preamble Start Supplemental Information
In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.
Mammography Quality Standards Act Requirements—21 CFR Part 900, OMB Control Number 0910-0309—Extension
The Mammography Quality Standards Act (Pub. L. 102-539) requires the establishment of a Federal certification and inspection program for mammography facilities; regulations and standards for accreditation and certification bodies for mammography facilities; and standards for mammography equipment, personnel, and practices, including quality assurance. The intent of these regulations is to assure safe, reliable, and accurate mammography on a nationwide level. Under the regulations, as a first step in becoming certified, mammography facilities must become accredited by an FDA-approved accreditation body (AB). This requires undergoing a review of their clinical images and providing the AB with information showing that they meet the equipment, personnel, quality assurance, and quality control standards, and have a medical reporting and recordkeeping program, a medical outcomes audit program, and a consumer complaint mechanism. On the basis of this accreditation, facilities are then certified by FDA or an FDA-approved State certification agency and must prominently display their certificate. These actions are taken to ensure safe, accurate, and reliable mammography on a nationwide basis.
The following sections of Title 21 of the Code of Federal Regulations (CFR) are not included in the burden tables because they are considered usual and customary practice and were part of the standard of care prior to the implementation of the regulations. Therefore, they resulted in no additional burden: 21 CFR 900.12(c)(1) and (3) and 900.3(f)(1). Section 900.24(c) was also not included in the burden tables because if a certifying State had its approval withdrawn, FDA would take over certifying authority for the affected facilities. Because FDA already has all the certifying State's electronic records, there wouldn't be an additional reporting burden.
We have rounded numbers in the “Total Hours” column in all three burden tables. (Where the number was a portion of 1 hour, it has been rounded to 1 hour. All other “Total Hours” have been rounded to the nearest whole number.)Start Printed Page 55464
We do not expect any respondents for § 900.3(c) because all four ABs are approved until April 2020.
In the Federal Register of June 8, 2016 (81 FR 36924), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received.
FDA estimates the burden of this collection of information as follows:
|Activity/21 CFR Section/Form FDA No.||Number of respondents||Number of responses per respondent||Total annual responses||Average burden per response||Total hours 1||Total capital costs (in dollars)||Total operating and maintenance costs (in dollars)|
|Notification of intent to become an AB—900.3(b)(1)||0.33||1||0.33||1||1|
|Application for approval as an AB; full 2—900.3(b)(3)||0.33||1||0.33||320||106||10,000|
|Application for approval as an AB; limited 3—900.3(b)(3)||5||1||5||30||150|
|AB renewal of approval—900.3(c)||0||1||0||15||1|
|AB application deficiencies—900.3(d)(2)||0.1||1||0.1||30||3|
|AB resubmission of denied applications—900.3(d)(5)||0.1||1||0.1||30||3|
|Letter of intent to relinquish accreditation authority—900.3(e)||0.1||1||0.1||1||1|
|Summary report describing all facility assessments—900.4(f)||330||1||330||7||2,310||77,600|
|AB reporting to FDA; facility 4—900.4(h)||8,654||1||8,654||1||8,654||4,327|
|AB reporting to FDA; AB 5—900.4(h)||5||1||5||10||50|
|AB financial records—900.4(i)(2)||1||1||1||16||16|
|Former AB new application—900.6(c)(1)||0.1||1||0.1||60||6|
|Reconsideration of accreditation following appeal—900.15(d)(3)(ii)||1||1||1||2||2|
|Application for alternative standard—900.18(c)||2||1||2||2||4|
|Alternative standard amendment—900.18(e)||10||1||10||1||10|
|Certification agency application—900.21(b)||0.33||1||0.33||320||106||208|
|Certification agency application deficiencies—900.21(c)(2)||0.1||1||0.1||30||3|
|Certification electronic data transmission—900.22(h)||5||200||1000||0.083||83||30,000|
|Changes to standards—900.22(i)||2||1||2||30||60||20|
|Certification agency minor deficiencies—900.24(b)||1||1||1||30||30|
|Appeal of adverse action taken by FDA—900.25(a)||0.2||1||0.2||16||3|
|Inspection fee exemption—Form FDA 3422||700||1||700||0.25||175|
|1 Total hours have been rounded.|
|2 One time burden.|
|3 Refers to accreditation bodies applying to accredit specific full-field digital mammography units.|
|4 Refers to the facility component of the burden for this requirement.|
|5 Refers to the AB component of the burden for this requirement.|
|Activity/21 CFR Section||Number of recordkeepers||Number of records per recordkeeper||Total annual records||Average burden per recordkeeping||Total hours 1||Total capital costs (in dollars)||Total operating and maintenance costs (in dollars)|
|AB transfer of facility records—900.3(f)(1)||0.1||1||0.1||0||1|
|Start Printed Page 55465|
|Consumer complaints system; AB—900.4(g)||5||1||5||1||5|
|Documentation of interpreting physician initial requirements—900.12(a)(1)(i)(B)(2)||87||1||87||8||696|
|Documentation of interpreting physician personnel requirements—900.12(a)(4)||8,654||4||34,616||1||34,616|
|Permanent medical record—900.12(c)(4)||8,654||1||8,654||1||8,654||28,000|
|Procedures for cleaning equipment—900.12(e)(13)||8,654||52||450,008||0.083||37,351|
|Consumer complaints system; facility—900.12(h)(2)||8,654||2||17,308||1||17,308|
|Certification agency conflict of interest—900.22(a)||5||1||5||1||5|
|Processes for suspension and revocation of certificates—900.22(d)||5||1||5||1||5|
|Processes for appeals—900.22(e)||5||1||5||1||5|
|Processes for additional mammography review—900.22(f)||5||1||5||1||5|
|Processes for patient notifications—900.22(g)||3||1||3||1||3||30|
|Evaluation of certification agency—900.23||5||1||5||20||100|
|1 Total hours have been rounded.|
|Activity/21 CFR Section||Number of respondents||Number of disclosures per respondent||Total annual disclosures||Average burden per disclosure||Total hours 2||Total operating and maintenance costs (in dollars)|
|Notification of facilities that AB relinquishes its accreditation—900.3(f)(2)||0.1||1||0.1||200||20||50|
|Clinical images; facility 3—900.4(c), 900.11(b)(1) and (2)||2,885||1||2,885||1.44||4,154|
|Clinical images; AB 4—900.4(c)||5||1||5||416||2,080||230,773|
|Phantom images; facility 3—900.4(d), 900.11(b)(1) and (2)||2,885||1||2,885||0.72||2,077|
|Phantom images; AB 4—900.4(d)||5||1||5||208||1,040|
|Annual equipment evaluation and survey; facility 3—900.4(e), 900.11(b)(1) and (2)||8,654||1||8,654||1||8,654||8,654|
|Annual equipment evaluation and survey; AB 4—900.4(e)||5||1||5||1,730||8,650|
|Provisional mammography facility certificate extension application—900.11(b)(3)||0||1||0||0.5||1|
|Start Printed Page 55466|
|Mammography facility certificate reinstatement application—900.11(c)||312||1||312||5||1,560||24,000,000|
|Lay summary of examination—900.12(c)(2)||8,654||5,085||44,055,590||0.083||3,652,464|
|Lay summary of examination; patient refusal 5—900.12(c)(2)||87||1||87||0.5||44|
|Report of unresolved serious complaints—900.12(h)(4)||20||1||20||1||20|
|Information regarding compromised quality; facility 3—900.12(j)(1)||20||1||20||200||4,000||300|
|Information regarding compromised quality; AB 4—900.12(j)(1)||20||1||20||320||6,400||600|
|Patient notification of serious risk—900.12(j)(2)||5||1||5||100||500||19,375|
|Reconsideration of accreditation—900.15(c)||5||1||5||2||10|
|Notification of requirement to correct major deficiencies—900.24(a)||0.4||1||0.4||200||80||68|
|Notification of loss of approval; major deficiencies—900.24(a)(2)||0.15||1||0.15||100||15||25.50|
|Notification of probationary status—900.24(b)(1)||0.3||1||0.3||200||60||51|
|Notification of loss of approval; minor deficiencies—900.24(b)(3)||0.15||1||0.15||100||15||25.50|
|1 There are no capital costs associated with this collection of information.|
|2 Total hours have been rounded.|
|3 Refers to the facility component of the burden for this requirement.|
|4 Refers to the AB component of the burden for this requirement.|
|5 Refers to the situation where a patient specifically does not want to receive the lay summary of her exam.|
Dated: August 15, 2016.
Associate Commissioner for Public Health Strategy and Analysis.
[FR Doc. 2016-19808 Filed 8-18-16; 8:45 am]
BILLING CODE 4164-01-P